Cargando…
Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas
Adult rhabdomyosarcoma (RMS) represents an uncommon entity with an incidence of less than 3% of all soft tissue sarcomas (STS). Consequently, the natural history and the clinical management of this disease are infrequently reported. In order to fill this gap, we investigated the molecular biology of...
Autores principales: | De Vita, Alessandro, Vanni, Silvia, Fausti, Valentina, Cocchi, Claudia, Recine, Federica, Miserocchi, Giacomo, Liverani, Chiara, Spadazzi, Chiara, Bassi, Massimo, Gessaroli, Manlio, Campobassi, Angelo, De Luca, Giovanni, Pieri, Federica, Farnedi, Anna, Franchini, Eugenia, Ferrari, Anna, Domizio, Chiara, Cavagna, Enrico, Gurrieri, Lorena, Bongiovanni, Alberto, Riva, Nada, Calpona, Sebastiano, Di Menna, Giandomenico, Debonis, Silvia Angela, Ibrahim, Toni, Mercatali, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584142/ https://www.ncbi.nlm.nih.gov/pubmed/34768995 http://dx.doi.org/10.3390/ijms222111564 |
Ejemplares similares
-
The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models
por: De Vita, Alessandro, et al.
Publicado: (2021) -
BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)
por: Recine, Federica, et al.
Publicado: (2019) -
A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences
por: De Vita, Alessandro, et al.
Publicado: (2022) -
Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis
por: Bongiovanni, Alberto, et al.
Publicado: (2020) -
mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
por: Spadazzi, Chiara, et al.
Publicado: (2019)